Atorvastatin improves sputum conversion and chest X-ray severity score
The International Journal of Tuberculosis and Lung Disease · 01.12.2023 · 27 (12) · 912-917
DOI: 10.5588/ijtld.23.0190 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, erschienen am 01.12.2023. Verfasst von O O Adewole und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Obafemi Awolowo University, Ile Ife, Department of Medicine, Obafemi Awolowo University Teaching Hospitals Ile Ife. Hauptthemen laut MEDLINE: Sputum, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 15-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND: We report the results of a phase IIB study investigating the safety and effectiveness of atorvastatin use with standard anti-TB drugs. METHODS: In this multicentre, open-labelled study, we recruited treatment-naÏve patients with uncomplicated pulmonary TB aged at least 18 years. Participants were randomly assigned to standard-of-care or standard-of-care plus oral dose of atorvastatin (40 mg) daily for 2 months. Primary end points were safety measured by the number of participants with severe adverse events and effectiveness measured by the number of participants with negative sputum culture. Secondary endpoint was chest X-ray (CXR) severity score. RESULTS: Of the 185 participants screened, 150 were enrolled and equally assigned to the standard-of-care and atorvastatin groups. Adverse event severity was similar in the two groups. There was increased frequency of muscle pain in the trial group (12/75, 16% vs. 4/75, 5%). For efficacy analysis, respectively 64 (97%) and 57 (85.1%) patients in the trial and control groups had culture-negative results ( P = 0.02) and experienced a reduction in CXR severity score of respectively 37% and 22%, with a mean difference of 1.4–4.9%. CONCLUSION: Atorvastatin is safe and associated with improved microbiological and radiological outcomes in TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Obafemi Awolowo University, Ile Ife, Department of Medicine, Obafemi Awolowo University Teaching Hospitals Ile Ife.
- Department of Medicine, Obafemi Awolowo University Teaching Hospitals Ile Ife, Medical Pharmacology & Therapeutic Department, Obafemi Awolowo University Ile Ife.
- Department of Medicine, Kaduna State University, Kaduna.
- Department of Medicine, Usman Fodiyo University, Sokoto, Sokoto.
- Departments of Radiology, and.
- Departments of Chemical Pathology, Obafemi Awolowo University/Teaching Hospitals Ile Ife.
Zitieren
APA
Adewole, O. O., Omotoso, B. A., Ogunsina, M., Aminu, A., Ayoola, O., Adedeji, T., Awopeju, O. F., Sogaolu, O. M., Adewole, T. O., Odeyemi, A. O., Jiya, E., Andero, V., Ojo, O., Toyin, K., Akintomide, A. O., & Erhabor, G. E. (2023). Atorvastatin improves sputum conversion and chest X-ray severity score. The International Journal of Tuberculosis and Lung Disease, 27(12), 912-917. https://doi.org/10.5588/ijtld.23.0190
Vancouver
Adewole OO, Omotoso BA, Ogunsina M, Aminu A, Ayoola O, Adedeji T, et al. Atorvastatin improves sputum conversion and chest X-ray severity score. The International Journal of Tuberculosis and Lung Disease. 2023;27(12):912-917. doi:10.5588/ijtld.23.0190
BibTeX
@article{Adewole2023,
author = {Adewole, O O and Omotoso, B A and Ogunsina, M and Aminu, A and Ayoola, O and Adedeji, T and Awopeju, O F and Sogaolu, O M and Adewole, T O and Odeyemi, A O and Jiya, E and Andero, V and Ojo, O and Toyin, K and Akintomide, A O and Erhabor, G E},
title = {Atorvastatin improves sputum conversion and chest X-ray severity score},
journal = {The International Journal of Tuberculosis and Lung Disease},
year = {2023},
volume = {27},
number = {12},
pages = {912--917},
doi = {10.5588/ijtld.23.0190}
}
EUVIMED